Clinical trial
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus…
NCT03299049 · ViiV Healthcare, Industry · Active, not recruiting
Key facts
| NCT number | NCT03299049 |
|---|---|
| Title | Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults |
| Official title | A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults Who Are Virologically Suppressed |
| Acronym | ATLAS-2M |
| Lead sponsor | ViiV Healthcare, Industry |
| Collaborators | Janssen Research & Development, LLC Industry |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Cabotegravir Tablets, Rilpivirine Tablets, Cabotegravir Injectable Suspension, Rilpivirine Injectable Suspension |
| Enrollment | 1,049 |
| Start date | Oct 27, 2017 |
| Primary completion | Jun 6, 2019 |
| Completion | Dec 31, 2029 |
| First posted | Oct 2, 2017 |
| Last update posted | Aug 22, 2025 |
| Countries | Argentina, Australia, Canada, France, Germany, Italy, Mexico, Russia, South Africa, South Korea, Spain, Sweden and 1 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: